Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.77 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.72 |
| ▸ | CTSL | P07711 | 6/20 | 0.72 |
| ▸ | CTSS | P25774 | 3/20 | 0.72 |
| ▸ | CTSB | P07858 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25406813 | 1.00 | CTSK (0.77) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL4872585 | 1.00 | CTSK (0.77) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL14148467 | 1.00 | CTSK (0.77) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL2930262 | 1.00 | CTSK (0.77) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL20770085 | 1.00 | CTSK (0.77) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL7612532 | 0.95 | CTSK (0.71) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL7612544 | 0.95 | CTSK (0.71) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL7326845 | 0.95 | CTSK (0.70) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL1823902 | 0.95 | CTSK (0.76) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL222158 | 0.95 | CTSK (0.76) | CTSKCAPN1CTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148841-A1 | COMPOSITIONS AND METHODS RELATED TO IMMUNOGLOBULIN PROTEASES AND FUSIONS THEREOF | CARTESIAN THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | disclosed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4117718-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20220291237-A1 | Gene Expression Inflammatory Age and Its Uses | Edifice Health, Inc. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11041207-B2 | Method for predicting a subject's response to valproic acid therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2019046303-A1 | A METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-101384301-A | Proteasom or ups inhibitor for treating infections with influenza viruses | VIROLOGIK GMBH (DE) | 2009-03-11 | — | — | CN | disclosed |
| WO-1997049668-A1 | INHIBITIORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | CTSK 3457/4885CAPN1 4394/4885CTSL 3871/4885 |
| US-20240148841-A1 | COMPOSITIONS AND METHODS RELATED TO IMMUNOGLOBULIN PROTEASES AND FUSIONS THEREOF | IGSF11, RPS27A, VSIG8 | CTSK 26/4885CAPN1 466/4885CTSL 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.